International journal of clinical practice
-
Int. J. Clin. Pract. · Jul 2021
Randomized Controlled TrialEffects of Melatonin Supplementation on Serum Oxidative Stress Markers and Disease Activity in Systemic Lupus Erythematosus Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
Considering pathological significance of oxidative stress in systemic lupus erythematosus (SLE), current research aimed to evaluate the effects of melatonin supplementation on oxidative stress markers and disease activity in SLE. ⋯ This study demonstrated affirmative effects of melatonin in decreasing oxidative stress in SLE patients without any effect on disease activity. Further investigations are required to affirm these primitive findings and to achieve concise conclusions.What's known Free radical damage and oxidative stress has a remarkable function in systemic lupus erythematosus (SLE) pathogenesis. Products derived from oxidative modification cascades are found in biological fluids and their redundancy has a correlation with disease activity and organ damage in SLE. Dietary supplements, which decrease oxidative stress, would be useful in managing SLE. Melatonin is a potent antioxidant and has anti-inflammatory and immunomodulatory characteristics. Limited in vitro and animal studies are available indicating desirable effects of melatonin in preventing from SLE organ damage, thereby opening a new area of investigation that can contribute to using melatonin as a therapy or co-therapy for SLE. What's new Melatonin supplementation caused significant reduction in serum MDA compared with baseline and placebo group. Serum TAC level did not change significantly in the melatonin group compared with baseline and placebo group. Furthermore, melatonin supplementation did not cause significant change in disease activity compared to baseline and placebo group.
-
Int. J. Clin. Pract. · Jul 2021
Meta AnalysisRisk factors of the severity of COVID-19: A meta-analysis.
We intend to identify some probable risk factors that are responsible for the severity of COVID-19 using a meta-analysis. ⋯ The findings of this research may be beneficial to identify patients with higher risks to provide additional medical attention from the very beginning of the treatment.
-
Int. J. Clin. Pract. · Jul 2021
The Role of Serum Albumin/Globulin Ratio in Combination with Prognostic Risk Indexes of Febrile Neutropenia.
The aim of this study was to evaluate the effect of the serum albumin/globulin ratio (AGR) on the 30-day mortality of febrile neutropenia (FEN). The second aim of the study was to evaluate the effect of the combination of the AGR with the Multinational Association for Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) risk indexes on 30-day mortality of FEN. ⋯ A low AGR in a patient with FEN was found to be associated with an increased risk of 30-day mortality. Combining the AGR with MASCC and CISNE risk indexes might increase the predictive value of these scoring systems on 30-day mortality.
-
Int. J. Clin. Pract. · Jul 2021
Meta AnalysisHorse riding simulators in treatment of chronic low back pain: a meta-analysis.
The use of horse-riding simulators in the treatment of chronic low back pain has drawn considerable attention for its efficacy and acceptability to reduce chronic low back pain; because of the similarities in movements provided by equine-assisted therapies and the possible accessibility advantages. However, the results are conflicting. This study aimed to perform a meta-analysis of randomised controlled trials to assess the impact of treatments based on horse-riding simulators on chronic low back pain. ⋯ Using horse-riding simulators may lower the risk of chronic low back pain. This relationship forces us to recommend the use of horse-riding simulators to avoid any complications that could occur with chronic low back pain.
-
Int. J. Clin. Pract. · Jul 2021
Multicenter StudyThe Efficacy of Rituximab in Patients with Neuromyelitis Optica Spectrum Disorder: a Real-World Study from Turkey.
Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity. ⋯ Rituximab therapy is efficacious in the treatment of Turkish NMOSD patients independent of the presence of the anti-AQP4-IgG antibody.